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STATEMENT OF TRANSLATIONAL RELEVANCE 
MK-2206 is a novel, specific, oral inhibitor of AKT, which is deregulated in 
multiple cancers. The study of different schedules of targeted agents is critical for 
their optimal application. The maximum tolerated dose (MTD) of MK-2206 was 
previously established at 60mg on alternate days (QOD). Due to a long half-life of 
60h-80h, MK-2206 was evaluated in a weekly schedule for comparison with QOD 
dosing in this study. The MK-2206 weekly schedule appeared to be similarly 
tolerated to QOD dosing, while pharmacodynamic studies using novel quantitative 
electrochemiluminescence assays in serially-obtained tumor and platelet-rich plasma 
(PRP) specimens confirmed significant AKT blockade with both continuous QOD and 
intermittent schedules of MK-2206. Functional imaging studies demonstrated that 
complex multiparametric MRI protocols may be effectively implemented in phase I 
trials. The intermittent weekly MTD of 200mg of MK-2206 established in this study is 
currently used in multiple phase II monotherapy and combination studies in defined 
patient populations. 
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ABSTRACT  
Purpose: Multiple cancers harbor genetic aberrations that impact AKT signaling. 
MK-2206 is a potent pan-AKT inhibitor with a maximum tolerated dose (MTD) 
previously established at 60mg on alternate days (QOD). Due to a long half-life (60-
80h), a weekly (QW) MK-2206 schedule was pursued to compare intermittent QW 
and continuous QOD dosing. 
Experimental Design: Patients with advanced cancers were enrolled onto a QW 
dose-escalation phase I study to investigate the safety and pharmacokinetic-
pharmacodynamic profiles of tumor and platelet-rich plasma (PRP). The QOD MTD 
of MK-2206 was also assessed in patients with ovarian and castration-resistant 
prostate cancers, and patients with advanced cancers undergoing multiparametric 
functional magnetic resonance imaging (MRI) studies, including dynamic contrast-
enhanced MRI, diffusion-weighted imaging, magnetic resonance spectroscopy and 
intrinsic susceptibility-weighted MRI.  
Results: Seventy-one patients were enrolled; 38 patients had 60mg MK-2206 QOD, 
while 33 received MK-2206 at 90mg, 135mg, 150mg, 200mg, 250mg, and 300mg 
QW. The QW MK-2206 MTD was established at 200mg following dose-limiting rash 
at 250mg and 300mg. QW dosing appeared to be similarly tolerated to QOD, with 
toxicities including rash, gastrointestinal symptoms, fatigue, and hyperglycemia. 
Significant AKT pathway blockade was observed with both continuous QOD and 
intermittent QW dosing of MK-2206 in serially-obtained tumor and PRP specimens. 
The functional imaging studies demonstrated that complex multiparametric MRI 
protocols may be effectively implemented in a phase I trial.  
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Conclusions: MK-2206 safely results in significant AKT pathway blockade in QOD 
and QW schedules. The intermittent dose of 200mg QW is currently used in phase II 
MK-2206 monotherapy and combination studies. 
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INTRODUCTION  
The serine-threonine kinase AKT is a central component of 
phosphatidylinositol 3-kinase (PI3K)-AKT signaling, and is critical to cell growth, 
survival, and proliferation [1]. Hyperactivation of this pathway is implicated as a key 
driver of multiple cancers, including prostate cancer and advanced ovarian tumors 
[2]. Many castration resistant prostate cancers (CRPC) have genomic abnormalities 
along the PI3K-AKT pathway, frequently through loss of PTEN, which supports 
androgen-independent tumor growth [3, 4]. The targeting of AKT in PTEN-loss 
CRPC tumors is supported by mouse models that indicate that AKT1 loss 
significantly reduces prostate cancer initiation [5]. The PI3K-AKT pathway is also 
frequently deranged in ovarian cancer [6]. Genetic amplification and mutation of 
PIK3CA are observed in approximately 40% and 12% of ovarian cancers, 
respectively [7, 8]. Similarly, AKT amplification is often encountered in ovarian 
cancer, although AKT mutations are rare [9, 10]. In view of this, different strategies 
have been developed to target AKT [2, 11].  
 
We have previously described the development of the potent, oral, allosteric 
AKT inhibitor MK-2206 (Merck & Co., Inc., Whitehouse Station, NJ, USA) [12, 13]. 
Following the observation of preclinical antitumor activity, a Phase I dose-escalation 
study of MK-2206 in 33 patients with advanced solid tumors was carried out, which 
established the maximum tolerated dose (MTD) at 60mg on alternate days (QOD) 
and demonstrated that MK-2206 safely induced significant AKT pathway blockade in 
tumor and hair follicles, with preliminary evidence of clinical activity [14]. 
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PD evaluation of AKT blockade involves the assessment of phosphorylation 
signals in normal tissue, such as the phosphorylation of pSer473 AKT and 
downstream substrates in platelet-rich plasma (PRP), as well as in tumor biopsies. 
Functional imaging can also be utilised to evaluate drug PD, including dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion weighted 
imaging (DWI), proton magnetic resonance spectroscopy (1H-MRS) and intrinsic 
susceptibility-weighted MR (ISW-MRI) [15]. DCE-MRI is a recognized tool for the 
characterization of tumor angiogenesis and the quantification of drug effects on 
tumor vascular permeability and perfusion [16-19]. DWI is also emerging as a 
biomarker of tumor necrosis and/or apoptosis [20, 21]. Furthermore, 1H-MRS can 
detect decreases in phosphocholine content after PI3K/AKT blockade [22, 23]. 
Changes in the imaging parameter for ISW-MRI (R2*) after chemotherapy have been 
described in breast cancers, but the measurement of antitumor changes has not 
been explored with antitumor targeted agents such as AKT inhibitors [24]. The 
utilization of these functional imaging techniques allows the characterization of the 
PD of novel molecular targeted agents in phase I studies. 
 
The study of different schedules of molecularly targeted therapies is critical for 
their optimal application, but is not often done in randomized phase II trials [25]. 
Thus, an alternative strategy is to undertake this during the expansion phase of a 
phase I clinical trial. In this study, cohorts of patients with CRPC, advanced ovarian 
cancer, and those undergoing multiparametric MRI studies were treated with 60mg 
QOD of MK-2206. In view of a half-life of 60h-80h observed [14], a QW schedule of 
MK-2206 was also evaluated to determine the safety and maximum tolerated dose 
(MTD)/recommended Phase II dose (RP2D) of MK-2206, and compared with QOD 
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dosing. In addition, electrochemiluminescence assays were utilized to quantify and 
compare the PD effects of MK-2206 in serial tumour and PRP specimens between 
both schedules of MK-2206, in parallel with pharmacokinetic (PK) studies.  
 
PATIENTS AND METHODS 
This was an open-label, dose-escalation Phase I study of continuous QOD 
and QW oral treatment with MK-2206, conducted at three centers (Royal Marsden 
NHS Foundation Trust, UK; South Texas Accelerated Research Therapeutics 
[START], TX; and H. Lee Moffitt Cancer Center and Research Institute, FL). The 
study was conducted in accordance with the Declaration of Helsinki and the 
International Conference on Harmonization Good Clinical Practice Guidelines and 
approved by relevant regulatory and independent ethics committees. 
 
Eligibility criteria 
Study inclusion criteria included written informed consent; age ≥18 years; 
patients with histologically or cytologically confirmed advanced solid tumors, who 
failed to respond to established therapies or for whom no proven treatments existed; 
Eastern Cooperative Oncology Group (ECOG) performance status [26] ≤1; previous 
surgery or chemotherapy ≥4 weeks; residual toxicity from prior treatment ≤grade 
(G)1; adequate bone marrow, renal, and hepatic function; fasting serum glucose 
≤1.1x the upper limit of normal (ULN) and HbA1c ≤8%.  
 
Study design 
For the QOD study, MK-2206 tablets were administered at 60mg QOD in 28-
day cycles to fasted patients in three different cohorts, comprising patients with 
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advanced CRPC (n=14), ovarian cancer (n=11) and those with tumors suitable for 
multiparametric MRI studies (n=16). For the QW study, a two-stage design was 
utilized. The first stage (dose-escalation phase) followed a standard three-plus-three 
design. Cohorts of three to six patients were to be treated at preplanned dose levels 
of 90, 135, 200 and 300 mg QW; intermediate-dose cohorts were permitted. The 
second stage (dose confirmation) employed a modification of the toxicity probability 
interval method [27]. The definition of DLTs included any MK-2206-related Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0 [28] ≥G4 
hematological toxicity, ≥G3 neutropenia with fever, or ≥G3 non-hematological toxicity 
(except for inadequately-treated G3 nausea, vomiting, or diarrhea).  
 
Safety 
Safety assessments were conducted at baseline, days 1, 2, 7, 15, 21, 27, and 
28 of cycle 1, weekly in cycle 2 and subsequently every month. All patients had a 
history, physical examination including full ophthalmologic assessment, 
electrocardiogram, 24h cardiac Holter monitoring, hematology and chemistry 
profiling, and urine analysis. In addition to glucose monitoring, serum c-peptide and 
whole blood HbA1c were measured at baseline and monthly. Adverse events (AEs) 
and laboratory variables were assessed using CTCAE version 3.0 [28].  
 
PK Analyses 
Plasma concentrations were analyzed by non-compartmental PK methods 
using WinNonLin (Scientific Consultant, Apex, NC; version 5.2.1, Pharsight, 
Mountain View, CA) (Supplementary methods). 
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Biomarker studies 
PD Biomarker analyses (pSer473 AKT, pSer9 GSK3E and pThr246 PRAS40) 
were undertaken on PRP and tumor, where available, using assays validated to 
Good Clinical Practice standards on the MesoScale Discovery (MSD®) technology 
and EnVisionTM technology platforms (Supplementary methods) [29]. 
 
Tumor response 
Radiological assessment of disease status was performed at baseline and 
every 8 weeks, according to Response Evaluation Criteria in Solid Tumors (RECIST 
1.1) [30]. Serum cancer antigen 125 (CA125) was assessed according to 
Gynecologic Cancer Intergroup (GCIG) criteria [31] and prostate specific antigen 
(PSA) according to the Prostate Cancer Working Group criteria (PCWG2) [32].  
 
MRI Methodology 
Patients were studied using a 1.5T Avanto MR Siemens system (Siemens 
Medical Systems, Erlangen, Germany) (Supplementary Methods). The 
multiparametric MRI protocol included DCE-MRI, DWI, 1H-MRS and ISW-MRI 
measurements. Median parameter values analyzed included transfer constant (Ktrans) 
for DCE-MRI, Apparent Diffusion Coefficient (ADC) for DWI, total choline/water 
(tCho/Water) ratio for 1H-MRS, and R2* for ISW-MRI, respectively [18, 19, 33, 34]. 
Patients were scanned at 4 time points: two studies pre-treatment as part of a 
measurement reproducibility cohort, and two studies on MK-2206 treatment on cycle 
1 day 7+/-1 and cycle 1 day 21+/-4. 
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RESULTS 
Seventy-one patients entered this study between April 2009 and January 
2011 and all were included in the safety analysis (Tables 1 and 2). Thirty-three 
patients received MK-2206 at escalating QW doses of 90mg (n=3), 135mg (n=5), 
200mg (n=17), 300mg (n=3) and intermediate doses of 250mg (n=3) and 150mg 
(n=2). Thirty-eight patients received MK-2206 in three 60mg QOD MTD expansion 
cohorts comprising CRPC, ovarian cancer and multiparametric MRI cohorts.  
 
Safety and tolerability 
Weekly (QW) schedule dose limiting toxicities (DLTs) 
Patients were enrolled into once weekly cohorts of 90mg (DLTs: 0 of 3 
patients), 135mg (DLTs: 0 of 4 patients), and 200mg (DLTs: 0 of 3 patients), prior to 
evaluation of a 300mg cohort where DLTs of G3 rash were observed in 3 of 3 
patients. An intermediate dose of 250mg QW was then explored and deemed to 
exceed the MTD with G3 rash observed in 2 of 3 patients. Therefore, an additional 3 
patients were enrolled at 200mg QW, where G3 rash was seen in 1 of 3 patients. 
Since only 1 of 6 patients experienced a DLT in the 200mg cohort during the dose 
escalation phase, this dose level was studied in a further expansion cohort of 11 
patients. Overall, in this study, 4 of 17 (23.5%) patients at 200mg QW experienced 
DLTs (G3 rash in 3 patients; G3 dermatitis acneiform in 1 patient). According to 
prespecified dose escalation/de-escalation rules, a lower intermediate dose of 
150mg (G3 rash in 1 of 2 patients) was also explored. However, for administrative 
and non-trial related reasons, the study was terminated prior to completion of 
enrolment to this cohort. Overall, based on review of PK/PD and safety/tolerability 
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data from both the QOD and QW dosing schedules, the MTD/RP2D of MK-2206 was 
established at 200mg QW. 
 
No DLTs were reported in patients who received MK-2206 at 90mg or 135mg 
QW. Dose interruptions lasting 2 to 4 weeks were required in patients with DLTs. 
Two patients withdrew study consent prior to re-initiation of therapy. One patient in 
the 200mg dose cohort resumed therapy at the same dose, while dose reduction to 
the next lower dose level occurred in the remaining 7 patients. No patients 
discontinued study therapy directly as a result of DLTs. While DLTs fully resolved in 
7 of these 10 patients within 1 to 2 weeks of onset, they resolved with sequelae of 
dry skin in 3 patients. No treatment-related G4-5 toxicities were observed.  
 
Weekly (QW) schedule safety and tolerability 
Overall, drug-related AEs were reported in 66.7% (22/33) of patients. The 
most common (≥10%) drug-related AEs were fatigue in 45.5% (15/33) of patients, 
rash in 42.4% (14/33) of patients, diarrhea and nausea in 27.3% (9/33) of patients 
each, vomiting in 24.2% (8/33) of patients, decreased appetite in 21.2% (7/33) of 
patients, stomatitis in 15.2% (5/33) of patients, and pruritus, increased alanine 
aminotransferase levels, and headaches in 12.1% (4/33) of patients each. The 
majority of these AEs were G1-2. G1 hyperglycemia was observed in 3.0% (1/33) of 
patients following 1 cycle of treatment with MK-2206 QW. Elevated blood glucose 
levels were observed in 57.6% (19/33) of patients who received MK-2206 QW. 
Elevations were mild and transient with onset occurring with similar frequencies 
during cycle 1 and subsequent cycles. Post-cycle 1 HbA1c values in all patients 
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assessed were <7%. In 4 of 6 patients assessed, C-peptide levels increased during 
the first cycle of treatment (range: 65.7%-166.6%).  
 
Three patients discontinued MK-2206 for drug-related AEs of G3 rash (n=1), 
G3 complete atrioventricular block (n=1), and G1 rash (n=1). Eleven of 33 patients 
interrupted study therapy due to drug-related AEs. Of these 11 patients, 2 patients 
resumed therapy at the same dose, 2 patients withdrew consent and did not resume 
study, and 7 patients required dose reduction to the next lower dose level. Dose 
interruptions of one day to 4 weeks was required prior to re-initiating study therapy.  
 
Alternate day (QOD) schedule DLTs 
DLTs occurred in 7 of 38 (18.4%) patients and included G3 rash (n=5), G3 
rash and G3 stomatitis (n=1), and G3 hyperglycemia (n=1) (Supplementary Table 
1). One patient discontinued study treatment due to G3 rash; this resolved within one 
week of stopping MK-2206. Overall, DLTs resulted in dose interruption in 6 patients. 
Among these 6 patients, study therapy was resumed within 1-2 weeks at the same 
dose of 60mg QOD (n=2), a reduced dose of 30mg QOD with subsequent dose 
escalation to 45mg QOD (n=2), and a reduced dose of 50mg QOD (n=1); dose 
interruption was followed by MK-2206 discontinuation in one patient due to disease 
progression. All DLTs resolved to baseline levels within 1-2 weeks of drug 
interruption; the DLT of G3 hyperglycemia was considered to be resolved with 
sequelae, as this patient with pre-existing glucose intolerance remained on 
metformin treatment. 
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Alternate day (QOD) schedule safety and tolerability 
The safety and tolerability of MK-2206 in a QOD schedule have previously 
been described in the dose-escalation study; thirty-three patients with advanced 
solid tumors were treated, with G1-2 rash the most common toxicity observed [14]. 
Other MK-2206-associated AEs included fatigue, gastrointestinal toxicities, and 
hyperglycemia. The QOD expansion cohorts in this study have confirmed that MK-
2206 is generally well tolerated in 38 patients at the MTD of 60mg QOD, with a 
similar toxicity profile to that observed during dose escalation (Supplementary Table 
1) [14].  
 
Following the first cycle of treatment, G1-2 hyperglycemia was observed in 
7.9% (3/38) of patients, and G3 hyperglycemia was observed in 2.6% (1/38) of 
patients. While not reported as AEs, blood glucose levels were noted to be elevated 
in 71.1% (27/38) of patients who received MK-2206 60mg QOD. The majority of 
elevations were mild and transient with onset occurring during the first cycle of 
therapy. Baseline and end of cycle 1 HbA1c levels were available in 76.3% (29/38) 
of patients, with 86.2% (25/29) of these patients demonstrating HbA1c levels of 
≤6.5% at both timepoints. In 2 patients with baseline levels ≤6.5%, end of cycle 1 
values were 7.3% and 8.3%, respectively. Baseline and end of cycle 1 C-peptide 
levels were available in 71.1% (27/38) of patients. In 85.2% (23/27) of these patients, 
C-peptide levels increased during the first cycle of treatment (range: 2.7% to 
495.5%). 
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Pharmacokinetics of MK-2206 
Weekly (QW) schedule pharmacokinetics 
Following administration in a QW schedule, MK-2206 was absorbed with a 
median time to maximum concentration (Tmax) of 4h-6h. As gastric emptying occurs 
within 1h-2h, the median Tmax of 4h-6h suggests that MK-2206 absorption probably 
occurs in both the small intestines and stomach. MK-2206 plasma concentrations 
declined in a mono-exponential manner after administration at 90mg, 135mg, 
200mg, 250mg, and 300mg QW (Figure 1A). The absorption and distribution of MK-
2206 are consistent with its relatively low solubility, but high permeability across 
physiological pH ranges. 
 
MK-2206 plasma concentrations exhibited high inter-patient variability with 
percent coefficient of variations (CVs) of area under the concentration-time curve 
(AUC) and maximum concentration (Cmax) ranging from 12% to 71%. AUC and Cmax 
increased in a dose-proportional manner within the dose range of 90mg to 300mg 
QW. Given the high inter-subject variability, there was no evidence of deviation from 
dose proportionality (Figures 1B and 1C). 
 
Table 3 summarizes PK parameters of MK-2206 following the first and last 
dose of cycle 1 QW dosing. Mean terminal elimination half-lives (t½) were 71.6h, 
88.9h, and 75.1h after administration of 90mg, 135mg, and 200mg doses, 
respectively, supporting the use of MK-2206 in QW and QOD dosing schedules. 
Accumulation ratio of MK-2206 expressed as the geometric mean ratios AUClast 
day:AUCfirst day or Cmaxlast day:Cmaxfirst day were 1.54 and 1.33, respectively, consistent 
with the terminal half-life, suggesting that elimination of MK-2206 did not change 
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after QW dosing of 200mg of MK-2206 (n=17). Accumulation ratios were slightly 
higher after QW dosing of 135mg MK-2206 (1.91 and 1.95, respectively); this is 
probably attributable to the low number of patients in the 135mg cohort (n=4).  
 
After QW administration in cycle 1, multiple-dose PK was only evaluable in 1 
patient in the 90mg, 150mg, or 250mg dose cohorts, and no patients were evaluable 
in the 300mg QW dose cohorts. Mean Cmax levels after 90mg to 250mg multiple QW 
dose administration (153 to 245 nM) were below the mean Cmax (365nM) of the no-
observed-adverse-effect-level (NOAEL) dose in dogs, while the mean Cmax after the 
first dose in the 300mg cohort (466nM) was higher that the Cmax at the NOAEL dose 
in dogs. The mean 48h (trough) plasma concentrations after multiple dose 
administration of 90mg to300mg QW MK-2206 exceeded the prespecified 56.8nM 
PK target for 70% inhibition of pAKT. After QW 90mg, 135mg, and 200mg QW 
dosing, the mean C48h values were 79.3nM, 158nM, and 187nM, respectively. 
 
Alternate day (QOD) schedule pharmacokinetics 
The peak plasma concentrations of MK-2206 occurred at median Tmax of 4h 
after administration of 60mg MK-2206 QOD in the expansion cohort and the t½ was 
64h, which was comparable to the PK values of patients in the dose escalation 
cohorts (Supplementary Table 2; Supplementary Figure 1) [14]. The accumulation 
ratio of MK-2206, assessed as AUClast day:AUCfirst day ratio, was 3.3, consistent with its 
elimination t½ and suggests no change in PK of MK-2206 after multiple dosing 
compared with a single dose. A similar accumulation ratio was observed in the dose 
escalation cohort [14].  
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Weekly (QW) versus alternate day (QOD) schedule pharmacokinetics 
Systemic exposure (AUCDaylast) of MK-2206 at the 60mg QOD schedule was 
comparable to exposure after the 200 mg QW schedule when normalized to the 3.3-
fold difference in dose (or 3.5-fold shorter dosing interval), while Cmax was about 2-
fold higher at the 200mg QW schedule compared with the 60mg QOD schedule. The 
terminal elimination half-lives were similar for the QOD and QW schedules, while 
trough concentrations after multiple 200mg QW dosing were lower than trough 
concentrations after multiple 60mg QOD dosing, relieving drug exposure for periods 
of time during treatment with the QW schedule of MK-2206. 
 
Pharmacodynamic biomarker analysis 
Weekly (QW) schedule pharmacodynamics 
The analysis of paired tumor biopsies from 5 patients receiving 200mg QW of 
MK-2206 (Figure 2A1) showed a significant suppression of pSer473 AKT when 
compared with paired pre-treatment samples. Overall, the pSer473 AKT signal 
decreased to 50.0% (range 37.5-60.3%; p=0.0003) of baseline levels on MK-2206 
treatment, confirming target modulation.  
 
The PD effects of MK-2206 treatment on pSer473 AKT (n=11) and pSer9 
GSK3β (n=11) phosphorylation at the 200mg MTD were also assessed sequentially 
in PRP specimens at multiple timepoints (Figure 2A2–2A3). The mean pSer473 
AKT signal post-MK-2206 was 19.8% at 24h (p<0.0001), 30.6% at 48h (p<0.0001), 
51.7% at 96h (p=0.0015) and 97.4% at 168h (p=0.92) of baseline levels (Figure 
2A2), while mean pSer9 GSK3β signal was 65.0% at 24h (p<0.0001), 82.3% at 48h 
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(p=0.012), 91.4% at 96h (p=0.56), and 117.2% at 168h (p=0.37) of baseline levels 
(Figure 2A3).  
 
Alternate day (QOD) schedule pharmacodynamics 
Paired tumor biopsies were obtained for biomarker analysis by MSD 
electrochemiluminescence assays from 3 patients receiving 60mg QOD of MK-2206 
(Figure 2B1). All 3 patients showed a significant suppression of pSer473 AKT when 
compared with paired pre-treatment samples. The mean pSer473 AKT levels 
decreased to 50.1% (range 45.3-56.2%; p=0.004) of baseline levels on MK-2206 
treatment, confirming target modulation. 
 
PD effects in PRP were also assessed serially at multiple timepoints from 29 
patients receiving the MTD of 60mg QOD of MK-2206 (Figure 2B2–2B4). The 
pSer473 AKT signal decreased significantly to mean values of 36.3% at 3h 
(p<0.0001), 27.9% at 6h (p<0.0001), 44.0% at 24h (p<0.0001), and 70.6% at 48h 
(p=0.045) of baseline levels (Figure 2B2).  Overall, pSer473 AKT levels decreased 
significantly by a mean of 55.3%, with maximum inhibition at 6h post-MK-2206. This 
suppression was sustained significantly for 48h when the next dose of drug was 
given. 
 
This inhibition of pSer473 AKT was associated with significant decreases in 
the phosphorylation of downstream substrates pSer9 GSK3β to mean levels of 
76.8% at 3h (p=0.009), 67.5% at 6h (p=0.0051), 102.9% at 24h (p=0.87), and 
116.1% at 48h (p=0.51) of baseline levels (Figure 2B3); and pThr246 PRAS40 to 
mean levels of 79.8% at 3h (p=0.005), 79.7% at 6h (p=0.0059), 86.9% at 24h 
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(p=0.030), and 91.4% at 48h (p=0.42) of baseline levels (Figure 2B4). With both 
pSer9 GSK3β substrates and pThr246 PRAS40, the maximum suppression was also 
at 6h post-MK-2206. A single patient was removed as an outlier according to Grubbs 
test for outliers (α=0.01), resulting in mean levels of 60.1% pSer473 AKT (p=0.0004) 
and 81.9% pThr246 PRAS40 (p=0.0019) at 48h. This confirmed the suppression of 
pSer473 AKT and its downstream target PRAS40 were significantly sustained to 48h 
in the remaining 28 patients on QOD dosing.  
 
Functional imaging cohort 
Sixteen patients were enrolled into the multiparametric MRI cohort, 
comprising DCE-MRI, DWI, 1H-MRS and ISW-MRI scans over 4 timepoints 
(Supplementary Tables 3-7). Each multiparametric MRI protocol lasted 45-50 
minutes per patient. Two baseline scans were undertaken at a mean period of 7.4 
days apart. Thirteen patients had 2 baseline studies each and were thus included in 
the reproducibility analysis. Of the 16 patients enrolled into this functional imaging 
cohort, four did not receive MK-2206 due to clinical deterioration (Supplementary 
Table 3). Of these remaining 12 patients, 1 patient had a non-enhancing lesion and 
so DCE-MRI analysis was not conducted; 1 patient had no detectable choline and 
therefore 1H-MRS analysis was not performed; and 5 patients had significant 
artefacts on ISW-MRI, and thus analysis was not undertaken. Therefore, the final 
evaluable imaging data sets included 11 patients for DCE-MRI, 12 patients for DWI, 
11 patients for 1H-MRS and 7 patients for ISW-MRI analysis (Supplementary 
Tables 4-7). 
 
Overall, the extent of all MRI parameter changes following treatment were 
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within the limits of data variability as determined by the analysis of the reproducibility 
cohort (Supplementary Figure 2). There was, however, a statistically significant 
increase in median tumor ADC in four patients on day 7. The increase in ADC was 
maintained in two of these patients on day 21. The baseline imaging measurements 
in these two patients suggested increased cellularity of the tumors with varying 
degrees of vascularity, prior to responding to MK-2206 treatment. In one of these 
patients (baseline median ADC = 100 x 10-5mm2s-1 and median Ktrans = 0.08 min-1), 
this response was associated with a moderate reduction in Ktrans of 20%, and there 
was a marginal reduction in the size of the tumor on restaging CT imaging after 6 
months of treatment (Supplementary Figure 3). In the other patient who had a more 
vascular tumor (baseline median ADC = 97.4 x10-5 mm2s-1 and median Ktrans = 1.14 
min-1), there was a significant increase in ADC values in keeping with of areas of 
necrosis within the enhancing and cellular rim of the tumor, while the central necrotic 
area of the tumor remained unchanged. This malignant lesion was stable by RECIST 
measurements on the restaging CT at week 8 of treatment (Supplementary Figure 
4).  
 
Antitumor activity 
The median duration of treatment for patients who received MK-2206 in a QW 
schedule was 8.1 weeks (range: 1.1 to 24.0 weeks), compared to 13.1 weeks 
(range: 8.7 to 28.0 weeks) for those in the QOD cohorts. Antitumor activity was 
reported in a 43-year-old female with ER/PR positive, HER2 negative metastatic 
breast cancer (Figure 3). Additional molecular characterization demonstrated 
PIK3CA exon 20 mutation on circulating nucleic acid analysis and low Ki67 
proliferation. She had previously received cyclophosphamide, doxorubicin, and 
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radiotherapy. Following 8 weeks of treatment with MK-2206 150mg QW, a 22% 
reduction in RECIST measurements of target lesions in the liver lesions, celiac axis, 
and para-aortic lymph nodes was noted. Post-treatment MRI demonstrated 
intratumoral necrosis of the liver and bone metastases. Additionally, an approximate 
36% reduction in CA15-3 was observed, and the patient remained on treatment for a 
total of 24 weeks. Apart from this patient, two patients with CRPC had RECIST SD 
for >6 months (range 6.5-7.5 months). 
 
DISCUSSION 
The QOD MTD/RP2D of 60mg of MK-2206 was generally well tolerated in 
patients with advanced cancers, as demonstrated previously [14]. The MTD/RP2D 
for QW dosing of MK-2206 was established at 200mg following the observation of 
DLTs of rash at the 250mg and 300mg QW dose levels of MK-2206. This DLT of 
rash is consistent with previous reports of AKT inhibition with MK-2206 and other 
PI3K-AKT pathway inhibitors [14, 35, 36]. Overall, the MTD/RP2D of the QW 
schedule of MK-2206 appeared to be similarly tolerated to QOD dosing (Table 2; 
Supplementary Tables 1 and 8) [14]. The pulsatile QW dosing of MK-2206 resulted 
in an intermittent rather than sustained blockade of AKT and downstream substrates 
observed with QOD dosing, thus potentially permiting some recovery of normal 
cellular function.  
 
The intermittent dosing of MK-2206 is supported by the observation of PK 
data demonstrating lower trough concentrations after 200mg QW dosing, in contrast 
to 60mg QOD dosing, relieving sustained drug pressure for periods of time during 
the QW schedule. PK parameters following the administration of 90mg-300mg MK-
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2206 QW in cycle 1 indicated no auto-induction of MK-2206 metabolizing enzymes 
as predicted by in vitro PK studies. Importantly, the terminal half-life of MK-2206 
(70h-90h) is supportive of a QW dosing schedule and Cmax values up to 250mg were 
below the NOAEL obtained in preclinical toxicology studies, while maintaining C48h 
values above the clinical monotherapy PK target for 70% inhibition of pSer473 AKT. 
Average steady-state trough MK-2206 concentrations at doses of at least 60mg 
QOD, and C48hr concentration of MK-2206 at doses of at least 90mg QW were on 
average greater than the concentrations required for 70% inhibition of pSer473 AKT 
in whole blood (57 nmol/L), a level identified in preclinical models as associated with 
antitumor activity for both continuous and intermittent dosing schedules, respectively. 
 
In this study, significant AKT inhibition was demonstrated in paired tumor 
biopsies and PRP specimens with both schedules of MK-2206. To our knowledge, 
this is the first demonstration of the feasibility of ‘real-time’ serial PRP sampling in a 
phase I trial setting using quantitative electrochemiluminescence assays (MSD®) and 
ELISA assays (EnVisionTM technology platform) to monitor multiple phosphoprotein 
changes in response to a novel molecular therapeutic, such as MK-2206. We have 
previously demonstrated the use of hair follicles as a surrogate tissue for the 
measurement of pThr246 PRAS40 PD effects, which confirmed AKT pathway 
blockade with MK-2206 [14].  
 
In addition, there were differential PD effects observed between QOD and 
QW dosing of MK-2206, specifically with regards to the phosphorylation levels of 
pSer473 AKT and downstream substrates pSer9 GSK3E and pThr246 PRAS40 in 
serial PRP sampling (Figure 2). For example, while continuous blockade of pSer473 
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AKT was observed at the QOD MTD of MK-2206, with the QW MTD there was an 
initial suppression of the phosphorylation signal for at least 96h, followed by partial 
recovery by the 168h timepoint prior to the next QW dosing timepoint. The 
establishment of such a pulsatile QW MTD has enabled MK-2206 to be taken 
forward in an intermittent rather than continuous schedule for combination studies. 
This schedule minimized potential MK-2206 toxicities and permitted a wider 
therapeutic window for the co-development of different combination regimens. This is 
especially critical since modest antitumor efficacy has been observed with MK-2206 
monotherapy and other PI3K-AKT pathway inhibitors, although anecdotal examples 
of patient benefit have been observed in this and other studies (Figure 3) [14, 36-
38]. 
 
MK-2206-related hyperglycemia and increased C-peptide levels were 
observed in most patients in both dosing schedules, consistent with PD inhibition of 
the AKT target and pathway [36]. These elevations in glucose were mainly mild and 
transient, suggesting effective homeostatic compensation with raised pancreatic 
insulin/C-peptide release in response to decreased glucose transport and 
metabolism due to AKT inhibition [36]. Although the exact mechanism of MK-2206-
induced hyperglycemia has not been fully elucidated, blockade of the PI3K pathway 
with other similar small molecule targeted inhibitors appears to be associated with 
peripheral insulin resistance, increased gluconeogenesis, and/or hepatic 
glycogenolysis [39]. 
 
The modest antitumor effects observed in this study with MK-2206 was 
despite statistically significant AKT blockade demonstrated in tumor and normal 
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tissue at the MTD of both schedules of MK-2206. Nevertheless, signaling through 
pSer9 GSK3β and pThr246 PRAS40 was less robustly suppressed, suggesting that 
effective downstream AKT pathway inhibition and biological effect was not achieved 
(Figure 2). The lack of RECIST antitumor responses may also potentially be due to 
the episodic recovery of AKT pathway signaling during MK-2206 treatment as 
suggested by the PRP PD data (Figure 2). Such pulsatile normalization of 
phosphorylated protein signals towards baseline levels may nevertheless be 
important for the transient return of normal cellular functions and minimization of MK-
2206-related toxicities. Ultimately, it will be important to define the extent and 
duration of target and signaling pathway inhibition required for optimal antitumor 
benefit and an acceptable therapeutic window.  
 
Furthermore, the limited antitumor activity observed may be due to signalling 
pathway crosstalk and/or disruption of feedback loops following the administration of 
MK-2206 monotherapy, justifying the development of this drug in molecularly-defined 
patient populations and in combination studies with other antitumor agents [25, 40]. It 
is therefore likely that the future development of AKT inhibitors will involve 
combination strategies with targeted agents against other rational targets including 
MEK, ER, AR, and the proteasome, as well as chemotherapies for the treatment of 
solid tumors. The use of an intermittent schedule of MK-2206 may improve 
tolerability and widen the therapeutic window of combination regimens. The pulsatile 
dosing of MK-2206 will also permit a higher degree, albeit shorter duration, of target 
blockade, which may potentially minimize tumor cell adaptation and eventual 
secondary drug resistance [25]. 
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MK-2206 has now been assessed in combination with the MEK inhibitor 
selumetinib (AstraZeneca; AZD6244) in patients with advanced solid tumors, 
including those with RAS mutant cancers [41]. Critically, the pulsatile QW schedule 
of MK-2206 improved the tolerability of this combination compared with continuous 
QOD dosing and enabled a RP2D to be established. Importantly, objective antitumor 
responses were observed in those with advanced KRAS mutant non-small cell lung 
carcinoma and ovarian cancers following treatment with this novel drug combination. 
 
The functional imaging study demonstrated for the first time that a combined 
DCE-MRI, DWI, ISW-MRI & 1H-MRS protocol may be implemented effectively in a 
phase I trial within a reasonable scanning time of 45-50min. The imaging protocol 
used in our studies also successfully combined DCE-MRI, DWI, and ISW-MRI data 
acquisition in the same plane through the same tumor volume, permitting the use of 
a common ROI across the different modalities included. Such an approach not only 
potentially reduces the time required for data analysis, but also offers the opportunity 
to explore tumor heterogeneity using a multiparameter analysis and multi-
segmentation approach. In our studies, the reproducibility measured was better with 
the DWI parameter (<10%) in contrast to DCE-MRI, 1H-MRS and ISW-MRI 
parameters (all >30%), which is likely to reflect differences in the tumoral 
characteristics measured and the range of imaging techniques employed.  
  
Individual examples of DWI and DCE-MRI responses were recorded 
(Supplementary Figures 3-4); however, a statistically significant cohort change in 
the image-derived parameters Ktrans, ADC, or tCho/Water ratio after administration of 
MK-2206 was not observed (Supplementary Figure 2). These observations may be 
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due primarily to the dose of 60mg QOD of MK-2206 being insufficient to result in 
alterations in vascular permeability tumor cellularity, as well as total choline and R2* 
levels that are detectable on the functional imaging undertaken; a higher MTD of 
200mg QW of MK-2206 may be necessary to achieve this. Such imaging studies 
should thus be considered in ongoing phase II trials evaluating this dose and 
schedule of MK-2206. The variability in baseline measurements for the imaging 
parameters could also mean that the sample size was inadequate to detect small 
changes. Furthermore, most of the lesions selected for MRI evaluation demonstrated 
a slow increase in overall size during the study, indicating a lack of antitumor 
response to MK-2206 monotherapy and suggesting that biologically significant AKT 
inhibition was possibly not achieved. 
 
In conclusion, we have used detailed safety, PK, and PD studies to establish 
the MTD/RP2D of MK-2206 in a QW schedule, which results in significant tumor cell 
target and pathway blockade while demonstrating tolerability for utility in different 
combination regimens. While we have confirmed impressive AKT blockade in PD 
studies, we have seen little evidence of antitumor activity. This schedule of MK-2206 
has now been taken forward into phase I/II trials involving both monotherapy and 
combination regimens in a wide range of cancers in defined patient populations [42].  
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TABLES 
Table 1: Patient baseline characteristics – all treated patients (N=71) 
 
60mg QOD schedule 
N=38 
n (%) 
QW schedule 
N=33 
n (%) 
Sex  Sex  
Male 20 (52.6) Male 18 (54.5) 
Female 18 (47.4) Female 15 (45.5) 
Median age, years 
(range) 63 (39-75) 
Median age, years 
(range) 59 (32-75) 
Cancer type  Cancer type  
Prostate 15 Prostate 7 
Colon/rectum 5 Colon/rectum 7 
Breast 1 Breast 6 
Ovarian 12 Ovarian 2 
Renal cell 3 Mesothelioma 2 
Othera 2 Otherb 9 
ECOG PS at 
screening  
ECOG PS at screening  
0 9 0 13 
1 29 1 20 
All prior therapiesc  All prior therapiesc  
1−2 8 1−2 13 
>2 30 >2 20 
aIncludes bile duct carcinoma and leiomyosarcoma (n=1 each) 
bIncludes bronchial carcinoma, leiomyosarcoma, melanoma, neuroendocrine tumor, 
pancreatic carcinoma, renal cell carcinoma, urothelial carcinoma, uterine carcinoma, 
and unknown primary carcinoma (all n=1) 
cIncludes chemotherapy, radiotherapy, hormone therapy and immunotherapies 
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Table 2: Treatment-related adverse events (AEs) for the QW dosing cohort. All values shown are the number of AEs occurring in 
n≥2 during cycle 1, and all cycles (parentheses) 
Common Treatment-Related Adverse Eventsa 
Cohort 90mg (n=3) 
135mg 
(n=5) 150mg (n=2) 200mg (n=17) 250mg (n=3) 300mg (n=3) 
AE G1 G1 G1 G2 G3 G1 G2 G3 G1 G2 G3 G1 G2 G3 
Gastrointestinal disorders 
Diarrhea 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Nausea 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 4 (4) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
Stomatitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 
Vomiting 1 (1) 0 (0) 2 (2) 0 (0) 0 (0) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
General disorders 
Fatigue 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (2) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
Metabolism and nutrition disorders 
Anorexia 0 (0) 0 (0) 0 (1) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Nervous system disorders 
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Dysgeusia 0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 
Skin and subcutaneous tissue disorders 
Dermatitis 
acneiform 
0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1c (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Dry skin 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Pruritus 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (2) 0 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Rashb 0 (0) 1 (1) 0 (0) 0 (0) 1c (3) 5 (9) 4 (4) 3c (3) 0 (1) 1 (2) 2c (2) 5 (6) 2 (2) 3c (3) 
aAll values shown represent number of AEs occurring in ≥2 patients during first cycle, and all cycles (parentheses).  If a patient experienced the same 
AE multiple times (at the same or different grade), the adverse event counted every time it occurred. 
No treatment-related G4-5 AEs were observed during the study. 
No treatment-related G2, 3 or 4 AEs were observed in the 90mg or 135mg dose cohorts. 
bAll preferred AE terms with "rash" (e.g. rash macular, rash papular, etc.) were collated into the single term of "Rash". 
cDose-limiting toxicity. 
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TABLE 3: MK-2206 Protocol 002 Preliminary Results: Summary PK Parameter Values Following Multiple QW Doses of 90, 135, 
150, 200, 250 and 300mg of MK-2206 in Male and Female Oncology Patients 
QW 
Dose 
(mg) 
N (Day 
1, Day 
last) 
AUC0-168h (nmol x h/L) 
Mean ± SD (%CV) 
Cmax  (nmol/L) 
Mean ± SD (%CV) 
 
C48h                                            
(nmol/L) 
Mean ± SD 
Tmax                                      
(h)a 
Apparent 
Terminal 
t1/2         
(h)b 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last Day 
90 3, 3 
6510 ± 3810 
(59%) 
10600 
± 
7520 
(71%) 
--d 
81.7 ± 
42.4 
(52%) 
153 ± 
98.0 
(64%) 
--d 
50.9 ± 
38.2 
79.3 ± 
33.7 
1.61 
6.0 
(4.0-
10.0) 
4.0 
(4.0-
4.0) 
71.6 ± 
12.2 
135 5, 4 
12000 ± 
4610 
(38%) 
20700 
± 
8780 
(42%) 
1.91 
199 ± 
98.9 
(50%) 
352 ± 
210 
(60%) 
1.95 
90.3 ± 
25.1 
158 ± 
59.2 
1.86 
4.0 
(4.0-
10.0) 
5.0 
(4.0-
24.0) 
88.9 ± 
26.9 
150 2, 1 20700 22600 --d 337 346 --d 155 185 --d (4.0- 4.0 64.4 
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QW 
Dose 
(mg) 
N (Day 
1, Day 
last) 
AUC0-168h (nmol x h/L) 
Mean ± SD (%CV) 
Cmax  (nmol/L) 
Mean ± SD (%CV) 
 
C48h                                            
(nmol/L) 
Mean ± SD 
Tmax                                      
(h)a 
Apparent 
Terminal 
t1/2         
(h)b 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last Day 
10.0) 
200 17, 13 
16400 ± 
5470 
(33%) 
23500 
± 
14700 
(63%) 
1.54 
264 ± 
75.8 
(29%) 
345 ± 
199 
(58%) 
1.33 
121 ± 
47.4 
187 ± 
113 
1.49 
6.0 
(4.0-
10.0) 
6.0 
(4.0-
24.0) 
75.1 ± 
14.7 
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QW 
Dose 
(mg) 
N (Day 
1, Day 
last) 
AUC0-168h                        
(nmol x h/L) 
Mean ± SD (%CV) 
Cmax  (nmol/L) 
Mean ± SD (%CV) 
 
C48hr                                             
(nmol/L) 
Mean ± SD 
Tmax                                      
(h)a 
Apparent 
Terminal t1/2         
(h)b 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last 
Day / 
Day1 
Ratioc 
Day 1 
Last 
Day 
Last Day 
250 3, 1 
14000 
± 2950 
(21%) 
10700 --d 
231 ± 
39.1 
(17%) 
169 --d 
103 ± 
19.6 
74.8 --d 
6.0 
(4.0-
6.0) 
4.0 53.7 
300 3, 0 
27700 
± 3320 
(12%) 
--d --d 
466 ± 
123 
(26%) 
--d --d 253 --d --d 
4.0 
(4.0-
6.0) 
--d --d 
aMedian (min - max) 
bHarmonic mean ±  pseudo SD 
cGeometric mean 
dSummary statistics not provided due to insufficient data 
 
Abbreviations: AUC, area under the concentration-time curve; Cmax: maximum measured plasma concentration; C48hr, plasma 
concentration 48 hours following dose (trough concentration); Tmax, time from dosing to maximum plasma concentration; t1/2, half-
life; SD, standard deviation 
Cancer Research. 
on September 23, 2014. © 2014 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 19, 2014; DOI: 10.1158/1078-0432.CCR-14-0868 
39 
 
FIGURE LEGENDS 
Figure 1A: Pharmacokinetic profile of MK-2206 in QW schedule. Mean plasma 
MK-2206 concentrations (nM) following the first dose of Cycle 1.  
 
Figure 1B: Pharmacokinetic profile of MK-2206 in QW schedule. MK-2206 
plasma AUC0-168hr (nM*hr) following the first dose of Cycle 1. 
 
Figure 1C: Pharmacokinetic profile of MK-2206 in QW schedule. MK-2206 
plasma Cmax (nM) following the first dose of Cycle 1. 
 
Figure 2A: Pharmacodynamic profile of MK-2206 in tumor and platelet-rich 
plasma (PRP) in a QW schedule. The analysis of paired tumor biopsies from 5 
patients receiving 200mg QW of MK-2206 (Figure 2A1) showed a significant 
suppression of pSer473 AKT, when compared with paired pre-treatment samples. 
Overall, the pSer473 AKT signal decreased to 50.0% (range 37.5-60.3%; p=0.0003) 
of baseline levels on MK-2206 treatment, confirming target modulation. The PD 
effects of MK-2206 treatment on pSer473 AKT (n=11) and pSer9 GSK3β (n=11) 
phosphorylation at the 200mg MTD were also assessed sequentially in PRP 
specimens at multiple timepoints (Figures 2A2 – 2A3). The mean pSer473 AKT 
signal post-MK-2206 was 19.8% at 24h (p<0.0001), 30.6% at 48h (p<0.0001), 51.7% 
at 96h (p=0.0015) and 97.4% at 168h (p=0.92) of baseline levels (Figure 2A2), while 
mean pSer9 GSK3β signal was 65.0% at 24h (p<0.0001), 82.3% at 48h (p=0.012), 
91.4% at 96h (p=0.56) and 117.2% at 168h (p=0.37) of baseline levels (Figure 2A3). 
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* p<0.05; **p<0.01; ***p<0.001 Paired t test compared to baseline. Points represent 
the levels of PD biomarkers as a percent of the baseline levels for individual patients 
and orange lines represent mean of all patients at that time point.  
 
Figure 2B: Pharmacodynamic profile of MK-2206 in platelet-rich plasma (PRP) 
and tumor in a QOD schedule. Paired tumor biopsies were also obtained for 
biomarker analysis by MSD® electrochemiluminescence assays from 3 patients 
receiving 60mg QOD of MK-2206. All 3 patients showed a significant suppression of 
pSer473 AKT, when compared with paired pre-treatment samples (Figure 2B1). The 
mean pSer473 AKT levels decreased to 50.1% (range 45.3-56.2%; p=0.004) of 
baseline levels on MK-2206 treatment, confirming target modulation. PD effects in 
PRP were also assessed serially at multiple timepoints from 29 patients receiving the 
MTD of 60mg QOD of MK-2206 (Figures 2B1-2B4). The pSer473 AKT signal 
decreased significantly to mean of 36.3% at 3h (p<0.0001), 27.9% at 6h (p<0.0001), 
44.0% at 24h (p<0.0001) and 70.6% at 48h (p=0.045) of baseline levels (Figure 
2B2).  Inhibition of pSer473 AKT was associated with significant decreases in the 
phosphorylation of downstream substrates pSer9 GSK3β to mean levels of 76.8% at 
3h (p=0.009), 67.5% at 6h (p=0.0051), 102.9% at 24h (p=0.87) and 9116.1% at 48h 
(p=0.51) of baseline levels (Figure 2B3); and pThr246 PRAS40 to mean levels of 
79.8% at 3h (p=0.005), 79.7% at 6h (p=0.0059), 86.9% at 24h (p=0.030) and 91.4% 
at 48h (p=0.42) of baseline levels (Figure 2B4). * p<0.05; **p<0.01; ***p<0.001 
Paired t-test compared to baseline. Points represent the levels of PD biomarkers as 
a percent of the baseline levels for individual patients and orange lines represent 
mean of all patients at that timepoint.  
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Figure 3: Best responder. A 43-year-old female with ER/PR positive, HER2 
negative metastatic breast cancer treated with 150mg QW of MK-2206. PD studies 
demonstrated maximal suppression of pSer473 AKT and its substrate pSer9 GSK3E 
at 24h, followed by a gradual recovery of phosphorylation signals from 48h in PRP. 
Points represent the levels of PD biomarkers as a percent of the baseline levels (A). 
Molecular characterization of circulating nucleic acids demonstrated a PIK3CA exon 
20 mutation and low Ki67 proliferation. The patient had previously received 
treatments including cyclophosphamide, doxorubicin and radiotherapy. Following 8 
weeks of treatment with MK-2206 150mg QW, there was a 22% reduction in RECIST 
measurements of her target lesions in the liver metastases, celiac axis and para-
aortic lymph nodes (B-C). Post treatment MRI demonstrated intratumoral necrosis in 
liver and bone lesions, as evidence by the high signal on anatomical T2 weighted 
images (D), and the high ADC values on DWI-MRI (overall lymph node mass ADC 
was 170 x 10-5 mm2/s; the mean ADC in the areas of necrosis was greater than 200 
x 10-5 mm2/s) (E). Consistent with these findings, CA15-3 levels decreased by 36% 
(6853U/ml to 4399U/ml) and the patient remained on treatment for a total of 24 
weeks before developing disease progression.  
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